CD274 and neoplasm: In summary, we proposed how overcoming the unfavorable limitations of current ICB immunotherapy with anti-PD-L1 peptide-conjugated prodrug nanoparticles (PD-NPs) via targeted tumor delivery of anti-PD-L1 peptide and DOX for combining PD-L1 blockade and ICD.